Faron Pharmaceuticals Oy BEXMAB Study Update Transcript
Greetings and welcome to the Faron Pharmaceuticals' BEXMAB study update. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the call over to your host, Dan Ferry of LifeSci Advisors. Thank you. You may begin.
Thank you, operator. Good morning, everyone, and welcome to the Faron Pharmaceuticals conference call to discuss the positive BEXMAB data from Phase 1/2 trial cohorts in patients with relapsed refractory AML and MDS and next steps for the program. A press release highlighting these updates is available on the Investors page of the corporate website at faron.com. We will be conducting a question-and-answer session at the end of the call.
Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements regarding our regulatory, product development, and commercialization plans, and research activities. These statements are subject to risks and uncertainties that could cause actual results to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
